Jinping Lai
YOU?
Author Swipe
View article: Intraoperative Frozen Section Diagnosis of Brain Rosai-Dorfman Disease Clinically and Radiologically Mimicking Meningioma
Intraoperative Frozen Section Diagnosis of Brain Rosai-Dorfman Disease Clinically and Radiologically Mimicking Meningioma Open
This case is a rare example of RDD clinically and radiologically mimicking meningioma and illustrates the importance of rigorous histological analysis for accurate diagnosis, particularly during the intraoperative consultation, to ensure p…
View article: The Role of TP53 Mutations in the Malignant Progression of Mucinous Borderline Ovarian Tumors: A Case Report and Literature Review
The Role of TP53 Mutations in the Malignant Progression of Mucinous Borderline Ovarian Tumors: A Case Report and Literature Review Open
The transition from MBOT to MOC is characterized by intricate genetic and epigenetic alterations, especially involving TP53 mutations. This progression presents considerable diagnostic challenges due to similarities with gastrointestinal c…
View article: A rapidly-growing friable nodule on the cheek
A rapidly-growing friable nodule on the cheek Open
Atypical fibroxanthoma and pleomorphic dermal sarcoma are on a spectrum of cutaneous tumors that present as ulcerated lesions in older adults. We present an 84-year-old man with pleomorphic dermal sarcoma, initially presenting as a bleedin…
View article: Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma
Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma Open
This study examines inhibiting galectin 1 (Gal1) as a treatment option for hepatocellular carcinoma (HCC). Gal1 has immunosuppressive and cancer-promoting roles. Our data showed that Gal1 was highly expressed in human and mouse HCC. The le…
View article: Editorial: The role of exosomes and organokines in metabolic and endocrine disease
Editorial: The role of exosomes and organokines in metabolic and endocrine disease Open
EDITORIAL article Front. Endocrinol., 21 April 2023Sec. Cellular Endocrinology Volume 14 - 2023 | https://doi.org/10.3389/fendo.2023.1198791
View article: Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
View article: Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
View article: Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
View article: Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
View article: Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)–positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation me…
View article: Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
View article: Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
View article: Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
View article: Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
View article: Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
View article: Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
View article: Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)–positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation me…
View article: Data from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Data from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tum…
View article: Supplementary Figure Legend from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure Legend from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 79K
View article: Supplementary Figure 4 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 4 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 119K, Targeted tBreg inactivation with BLC-arp/CpG-ODN
View article: Supplementary Figure 2 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 2 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 206K, Regulatory activity is mostly retained in human tBregs expressing low levels of CD20
View article: Supplementary Figure 5 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 5 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 96K, In vivo inactivation of tBregs with BLC-arp/CpG-ODN induces antitumor T cell responses
View article: Supplementary Figure 3 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 3 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 126K, Activity of tBregs is efficiently blocked by CpG-ODN
View article: Supplementary Figure 2 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 2 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 206K, Regulatory activity is mostly retained in human tBregs expressing low levels of CD20
View article: Supplementary Figure Legend from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure Legend from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 79K
View article: Supplementary Figure 1 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 1 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 1209K, tBregs express low levels of CD20
View article: Supplementary Figure 4 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Supplementary Figure 4 from Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L Open
PDF file - 119K, Targeted tBreg inactivation with BLC-arp/CpG-ODN